RBC Global Healthcare Conference: Global Head of Healthcare Investment Banking Darren Campili discusses the environment for fundraising, IPOs, and M&A
He shares his take on the ability for mid and small cap biotech companies to raise money and go public, which he describes as being very catalyst dependent.
5 days ago
RBC Global Healthcare Conference: US Large Cap Pharma Analyst Trung Huynh shares his take on the obesity market and rates Pfizer's last two major acquisitions
He discusses Lilly (his top pick) and the launch of Foundayo, and shares how he thinks about Pfizer's last two large acquisitions for Metsera and Seagen.
5 days ago
RBC Healthcare Conference: RBC Senior Analyst Luca Issi shares his take on biotech and comments on key companies he covers that have been in the news
He discusses Ionis, Arrowhead, REGENXBIO, uniQure, and more.
5 days ago
ASGCT 2026: Genetic Medicines Expert TJ Cradick highlights what are the key topics heading into the start of ASGCT
He highlights key issues around capsids and immunogenicity, in vivo engineering, using cell therapies for autoimmune, and, of course, how AI is affecting this science. Coverage brought to you by
May 12
Wharton Biotech Conference: MatchPlay CEO and Neuvation Ventures Managing Partner Mahesh Narayanan shares advice investing in people and maximizing talent in biotech
He shares advice for what areas of science PhDs might pursue in industry, how to success (get stuff done) and validating science.
May 11
Friedrich von Bohlen, Co-Founder & CEO of the data science company Molecular Health, has been at the forefront of biotech in Germany since the 1990's. He describes his work and thoughts on the sector.
He highlights the work of building Molecular Health's databases since it was founded in 2004, and how the company helps pharma and biotech companies make more informed and efficient drug development decisions. Plus, his thoughts on the state of biotech innovation in Germany and how he thinks the environment can be improved.
May 1
.png){kind=logo}
